Notably, the 70% MRD negativity rate in our venetoclax-HMA cohort may reflect dual epigenetic-apoptotic synergy: azacitidine upregulates tumor-associated antigens through global hypomethylation, while venetoclax enhances T-cell cytotoxicity by reducing PD-L1 expression on leukemic blasts. The gene discussed is CD274; the disease is neoplasm.